CN105861441A - Hepatoma cell line STL-C1 derived from human hepatoma a-carcinoma tissue and establishment method thereof - Google Patents
Hepatoma cell line STL-C1 derived from human hepatoma a-carcinoma tissue and establishment method thereof Download PDFInfo
- Publication number
- CN105861441A CN105861441A CN201610202256.XA CN201610202256A CN105861441A CN 105861441 A CN105861441 A CN 105861441A CN 201610202256 A CN201610202256 A CN 201610202256A CN 105861441 A CN105861441 A CN 105861441A
- Authority
- CN
- China
- Prior art keywords
- cell
- cancer
- hepatoma
- stl
- beside organism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 24
- 201000009030 Carcinoma Diseases 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract description 94
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 62
- 201000011510 cancer Diseases 0.000 claims abstract description 45
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 9
- 201000007270 liver cancer Diseases 0.000 claims description 48
- 208000014018 liver neoplasm Diseases 0.000 claims description 48
- 230000010412 perfusion Effects 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- 235000015097 nutrients Nutrition 0.000 claims description 17
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 16
- 102000029816 Collagenase Human genes 0.000 claims description 12
- 108060005980 Collagenase Proteins 0.000 claims description 12
- 229960002424 collagenase Drugs 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 10
- 238000011081 inoculation Methods 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 238000010276 construction Methods 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 238000010171 animal model Methods 0.000 claims description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 4
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 102000002070 Transferrins Human genes 0.000 claims description 2
- 108010015865 Transferrins Proteins 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000004026 insulin derivative Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000011160 research Methods 0.000 abstract description 15
- 238000002474 experimental method Methods 0.000 abstract description 13
- 238000000338 in vitro Methods 0.000 abstract description 9
- 238000004321 preservation Methods 0.000 abstract description 5
- 238000012546 transfer Methods 0.000 abstract description 5
- 208000005189 Embolism Diseases 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000002440 hepatic effect Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 230000004791 biological behavior Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 19
- 230000012010 growth Effects 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 16
- 230000001464 adherent effect Effects 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 210000003240 portal vein Anatomy 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000006399 behavior Effects 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 206010073069 Hepatic cancer Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010027458 Metastases to lung Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229940091258 selenium supplement Drugs 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000024678 Complex chromosomal rearrangement Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000610743 Psathyrotes ramosissima Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000258 photobiological effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610202256.XA CN105861441B (en) | 2016-04-01 | 2016-04-01 | A kind of liver cancer cell lines STL-C1 from human hepatocellular carcinoma cancer beside organism and its build system, method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610202256.XA CN105861441B (en) | 2016-04-01 | 2016-04-01 | A kind of liver cancer cell lines STL-C1 from human hepatocellular carcinoma cancer beside organism and its build system, method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105861441A true CN105861441A (en) | 2016-08-17 |
CN105861441B CN105861441B (en) | 2018-06-12 |
Family
ID=56626724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610202256.XA Expired - Fee Related CN105861441B (en) | 2016-04-01 | 2016-04-01 | A kind of liver cancer cell lines STL-C1 from human hepatocellular carcinoma cancer beside organism and its build system, method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105861441B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108795851A (en) * | 2017-04-27 | 2018-11-13 | 大连医科大学 | The method for building up of people's salivary adenoid cystic carcinoma carcinoma-associated fibroblasts system CAF-SA a kind of and its application |
CN108967417A (en) * | 2018-08-09 | 2018-12-11 | 爱克精医(北京)生物医药科技有限公司 | A kind of tumor tissues high activity storage transport liquid and preparation method thereof |
CN109055302A (en) * | 2018-08-28 | 2018-12-21 | 重庆医科大学附属第医院 | The method of separation, culture and the identification of HBV transgenic mice primary hepatocyte |
CN111321119A (en) * | 2020-03-18 | 2020-06-23 | 四川大学 | Liver cancer cell line suitable for large-scale serum-free adherent culture and establishment method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101597591A (en) * | 2008-06-06 | 2009-12-09 | 中国人民解放军第二军医大学东方肝胆外科医院 | A kind of hepatoma cell line of the people's of deriving from liver cancer and portal vein cancer and build system, method |
CN101693886A (en) * | 2009-08-10 | 2010-04-14 | 北京肿瘤医院 | Liver cancer cell line and application thereof |
US20120295349A1 (en) * | 2009-02-20 | 2012-11-22 | Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan | Mammal dedicated cell line from human hepatocellular carcinoma cell |
-
2016
- 2016-04-01 CN CN201610202256.XA patent/CN105861441B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101597591A (en) * | 2008-06-06 | 2009-12-09 | 中国人民解放军第二军医大学东方肝胆外科医院 | A kind of hepatoma cell line of the people's of deriving from liver cancer and portal vein cancer and build system, method |
US20120295349A1 (en) * | 2009-02-20 | 2012-11-22 | Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan | Mammal dedicated cell line from human hepatocellular carcinoma cell |
CN101693886A (en) * | 2009-08-10 | 2010-04-14 | 北京肿瘤医院 | Liver cancer cell line and application thereof |
Non-Patent Citations (1)
Title |
---|
江珊珊等: "肝癌肿瘤浸润淋巴细胞(TIL)体外扩增及特性研究", 《中国细胞生物学学报》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108795851A (en) * | 2017-04-27 | 2018-11-13 | 大连医科大学 | The method for building up of people's salivary adenoid cystic carcinoma carcinoma-associated fibroblasts system CAF-SA a kind of and its application |
CN108795851B (en) * | 2017-04-27 | 2022-03-18 | 大连医科大学 | Establishment method and application of human salivary adenoid cystic carcinoma related fibroblast cell line CAF-SA |
CN108967417A (en) * | 2018-08-09 | 2018-12-11 | 爱克精医(北京)生物医药科技有限公司 | A kind of tumor tissues high activity storage transport liquid and preparation method thereof |
CN108967417B (en) * | 2018-08-09 | 2019-05-10 | 爱克精医(北京)生物医药科技有限公司 | A kind of tumor tissues high activity storage transport liquid and preparation method thereof |
CN109055302A (en) * | 2018-08-28 | 2018-12-21 | 重庆医科大学附属第医院 | The method of separation, culture and the identification of HBV transgenic mice primary hepatocyte |
CN111321119A (en) * | 2020-03-18 | 2020-06-23 | 四川大学 | Liver cancer cell line suitable for large-scale serum-free adherent culture and establishment method and application thereof |
CN111321119B (en) * | 2020-03-18 | 2022-09-20 | 四川大学 | Liver cancer cell line suitable for large-scale serum-free adherent culture and establishment method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN105861441B (en) | 2018-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liang et al. | Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma | |
JP2023521878A (en) | Culture medium, culture method, and use thereof for epithelial cells of esophageal squamous cell carcinoma | |
Moutasim et al. | Cell migration and invasion assays | |
CN105861441A (en) | Hepatoma cell line STL-C1 derived from human hepatoma a-carcinoma tissue and establishment method thereof | |
CN102250840B (en) | Human pancreatic cancer cell line and its application | |
CN103865876A (en) | Method for primary culture of tumor cells | |
CN102465113B (en) | Human hepatoma carcinoma cell line and application thereof | |
CN103451148B (en) | People's normal bronchial epithelial cell and primary separation and Culture thereof and Secondary Culture method and purposes | |
CN105102614A (en) | Method for obtaining cell mass containing cancer stem cell | |
CN102719403B (en) | A kind of human pancreas's adenosquamous carcinoma clone and establishment method thereof and application | |
CN102690784B (en) | The foundation of hepatoma cell line HCC-LY10 and application | |
CN103881975B (en) | Human Prostate Cancer Cells and primary separation and Culture thereof and Secondary Culture method and purposes | |
CN104694476A (en) | Human non-small cell lung cancer cell line, and establishment method and application thereof | |
CN102329775B (en) | A kind of human pancreatic cancer cell to gemcitabine resistance and application thereof | |
CN110904026B (en) | Preparation method and application of hepatic precursor-like cells from different sources | |
CN103966327B (en) | The application of a kind of miR-27a and diagnostic kit thereof | |
CN107177551B (en) | Human intrahepatic bile duct cancer cell line with high tumor forming capability and application thereof | |
CN104195109A (en) | Human lung adenocarcinoma cell line and application thereof | |
CN101633922A (en) | Molecular marker hsa-miR-374a of breast carcinoma and application thereof | |
CN102181399B (en) | Mouse liver tumor cell line for highly expressing CD133 and preparation method thereof | |
CN104745530A (en) | Human hepatocellular carcinoma cell line, and establishing method and application thereof | |
CN105062973B (en) | One plant carries HPV feminine gender penis squamous cell carcinomas system that TP53 is mutated and application thereof | |
CN102168085A (en) | SiRNA for inhibiting expression of miR-130b gene and expression vector and application of siRNA or/and expression vector to preparation of medicament for improving treatment effect of liver cancer | |
CN103911343B (en) | A kind of multiple organ shifts human bladder cancer cell | |
CN108977410B (en) | Pancreatic cancer in-situ cancer cell line of Chinese people |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Hongyang Inventor after: Yan Hexin Inventor after: Wang Mingda Inventor after: Wu Han Inventor after: Fu Gongbo Inventor after: Zhou Xu Inventor after: Zeng Min Inventor after: Huang Weijian Inventor before: Wang Hongyang Inventor before: Yan Hexin Inventor before: Wang Mingda Inventor before: Wu Han Inventor before: Fu Gongbo Inventor before: Zhou Xu |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180612 |